Equities Analysts Set Expectations for MLTX Q2 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for shares of MoonLake Immunotherapeutics in a research note issued to investors on Monday, July 20th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.75) per share for the quarter, up from their prior estimate of ($0.81). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($3.71) per share. HC Wainwright also issued estimates for MoonLake Immunotherapeutics’ Q3 2026 earnings at ($0.62) EPS, Q4 2026 earnings at ($0.59) EPS, FY2026 earnings at ($2.90) EPS, Q1 2027 earnings at ($0.57) EPS, Q2 2027 earnings at ($0.67) EPS, Q3 2027 earnings at ($0.75) EPS, Q4 2027 earnings at ($0.55) EPS and FY2027 earnings at ($2.54) EPS.

A number of other equities research analysts have also weighed in on MLTX. BTIG Research restated a “buy” rating and issued a $30.00 price objective on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 9th. Leerink Partners increased their target price on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an “outperform” rating in a report on Wednesday, July 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a research note on Tuesday, May 12th. Finally, Needham & Company LLC boosted their price target on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, May 12th. Ten research analysts have rated the stock with a Buy rating, four have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $24.21.

MoonLake Immunotherapeutics Stock Up 5.3%

Shares of NASDAQ MLTX opened at $20.06 on Wednesday. MoonLake Immunotherapeutics has a one year low of $5.95 and a one year high of $62.75. The company has a debt-to-equity ratio of 0.39, a current ratio of 8.60 and a quick ratio of 8.60. The firm’s 50 day simple moving average is $18.91 and its two-hundred day simple moving average is $17.55. The stock has a market capitalization of $1.48 billion, a P/E ratio of -5.18 and a beta of 1.04.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.07).

Insider Activity at MoonLake Immunotherapeutics

In other news, CEO Da Silva Jorge Santos sold 68,289 shares of the firm’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $20.02, for a total value of $1,367,145.78. Following the transaction, the chief executive officer owned 2,774,893 shares in the company, valued at approximately $55,553,357.86. This trade represents a 2.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $19.43, for a total transaction of $971,500.00. Following the completion of the transaction, the insider directly owned 2,824,551 shares in the company, valued at approximately $54,881,025.93. The trade was a 1.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 250,000 shares of company stock valued at $4,919,138 in the last quarter. Corporate insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Large investors have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC bought a new position in shares of MoonLake Immunotherapeutics during the fourth quarter valued at about $26,000. EverSource Wealth Advisors LLC boosted its holdings in shares of MoonLake Immunotherapeutics by 221.1% during the first quarter. EverSource Wealth Advisors LLC now owns 2,867 shares of the company’s stock worth $53,000 after purchasing an additional 1,974 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of MoonLake Immunotherapeutics in the second quarter worth about $58,000. Russell Investments Group Ltd. grew its stake in shares of MoonLake Immunotherapeutics by 45.4% in the fourth quarter. Russell Investments Group Ltd. now owns 3,426 shares of the company’s stock worth $45,000 after purchasing an additional 1,069 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in MoonLake Immunotherapeutics during the 4th quarter valued at about $47,000. Institutional investors own 93.85% of the company’s stock.

More MoonLake Immunotherapeutics News

Here are the key news stories impacting MoonLake Immunotherapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating on MoonLake Immunotherapeutics and maintained a $45 price target, signaling continued bullish outlook from the analyst firm.
• Positive Sentiment: The firm lifted its EPS forecasts for several periods, including FY2026, FY2027, Q1 2027, Q2 2027, Q3 2027, Q4 2027, and select 2026 quarters, indicating improving earnings expectations for MoonLake Immunotherapeutics. HC Wainwright Reaffirms Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)
• Neutral Sentiment: The updates were mostly forecast revisions rather than new clinical or regulatory news, so the stock’s move appears tied to analyst sentiment and valuation outlook rather than a fundamental business event.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.